Skip to main content
SpringerLink
Log in
Book cover

Adult Acute Lymphocytic Leukemia pp 211–232Cite as

Treatment of Acute Lymphoblastic Leukemia in Young Adults

  • Chapter
  • First Online:

Part of the book series: Contemporary Hematology ((CH))

Abstract

Over the last 3 decades, progress in the treatment of acute lymphoblastic leukemia (ALL) in children has dramatically improved the outcome of patients, leading to cure rates of more than 80%. In adult ALL, the improvements in outcome have been modest with cure rates approximating 40%. In pediatric trials, patients older than 10 years of age are often considered high-risk patients and are treated more intensively. In adult trials, adolescents and young adults with ALL are considered as standard-risk patients and receive chemotherapy scheduled for patients up to 60 years of age. These divergent treatment approaches in adolescents led many pediatric and adult groups to compare their results in this subgroup of patients and to conclude that adolescents may benefit from treatment with pediatric regimens. In young adults, recent studies have demonstrated that outcome may be improved by pediatric-inspired reinforced chemotherapeutic strategies but also by allogeneic transplantation. In this chapter focusing on ALL in young adults, we summarize the specific biologic characteristics of the disease and the results of recent adult protocols. Therapeutic strategies inspired from pediatric approaches will be emphasized. The development of collaborative trials in optimized psychosocial environments will be required to steadily improve the results in this population of young adults.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Pui, C. H., & Evans, W. E. (1998). Acute lymphoblastic leukemia. The New England Journal of Medicine, 339(9), 605–615.

    Article  PubMed  CAS  Google Scholar 

  2. Hoelzer, D. (1993). Acute lymphoblastic leukemia–progress in children, less in adults. The New England Journal of Medicine, 329(18), 1343–1344.

    Article  PubMed  CAS  Google Scholar 

  3. Pui, C. H., & Evans, W. E. (2006). Treatment of acute lymphoblastic leukemia. The New England Journal of Medicine, 354(2), 166–178.

    Article  PubMed  CAS  Google Scholar 

  4. Gokbuget, N., & Hoelzer, D. (2009). Treatment of adult acute lymphoblastic leukemia. Seminars in Hematology, 46(1), 64–75.

    Article  PubMed  Google Scholar 

  5. Perentesis, J. P. (1997). Why is age such an important independent prognostic factor in acute lymphoblastic leukemia? Leukemia, 11(Suppl 4), S4–S7.

    PubMed  Google Scholar 

  6. Chessells, J. M., Hall, E., Prentice, H. G., Durrant, J., Bailey, C. C., & Richards, S. M. (1998). The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: A report from the MRC Paediatric and Adult Working Parties. Leukemia, 12(4), 463–473.

    Article  PubMed  CAS  Google Scholar 

  7. Plasschaert, S. L., Kamps, W. A., Vellenga, E., de Vries, E. G., & de Bont, E. S. (2004). Prognosis in childhood and adult acute lymphoblastic leukaemia: A question of maturation? Cancer Treatment Reviews, 30(1), 37–51.

    Article  PubMed  Google Scholar 

  8. Borkhardt, A., Cazzaniga, G., Viehmann, S., et al. (1997). Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood, 90(2), 571–577.

    PubMed  CAS  Google Scholar 

  9. Cayuela, J. M., Baruchel, A., Orange, C., et al. (1996). TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia. Blood, 88(1), 302–308.

    PubMed  CAS  Google Scholar 

  10. Copelan, E. A., & McGuire, E. A. (1995). The biology and treatment of acute lymphoblastic leukemia in adults. Blood, 85(5), 1151–1168.

    PubMed  CAS  Google Scholar 

  11. Goker, E., Lin, J. T., Trippett, T., et al. (1993). Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia, 7(7), 1000–1004.

    PubMed  CAS  Google Scholar 

  12. Maung, Z. T., Reid, M. M., Matheson, E., Taylor, P. R., Proctor, S. J., & Hall, A. G. (1995). Corticosteroid resistance is increased in lymphoblasts from adults compared with children: Preliminary results of in vitro drug sensitivity study in adults with acute lymphoblastic leukaemia. British Journal of Haematology, 91(1), 93–100.

    Article  PubMed  CAS  Google Scholar 

  13. Styczynski, J., Pieters, R., Huismans, D. R., Schuurhuis, G. J., Wysocki, M., & Veerman, A. J. (2000). In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia. British Journal of Haematology, 110(4), 813–818.

    Article  PubMed  CAS  Google Scholar 

  14. Mattano, L., Jr., Nachman, J., Ross, J., & Stock, W. (2006). Leukemias. In W. Bleyer, M. O’Leary, R. Barr, & L. Ries (Eds.), Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975–2000 (pp. 39–51). Bethesda, MD: National Cancer Institute (NIH Pub. No. 06-5767).

    Google Scholar 

  15. Albritton, K. H., Wiggins, C. H., Nelson, H. E., & Weeks, J. C. (2007). Site of oncologic specialty care for older adolescents in Utah. Journal of Clinical Oncology, 25(29), 4616–4621.

    Article  PubMed  Google Scholar 

  16. Howell, D. L., Ward, K. C., Austin, H. D., Young, J. L., & Woods, W. G. (2007). Access to pediatric cancer care by age, race, and diagnosis, and outcomes of cancer treatment in pediatric and adolescent patients in the state of Georgia. Journal of Clinical Oncology, 25(29), 4610–4615.

    Article  PubMed  Google Scholar 

  17. Nachman, J., Sather, H. N., Buckley, J. D., et al. (1993). Young adults 16-21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment. Cancer, 71(10 Suppl), 3377–3385.

    Article  PubMed  CAS  Google Scholar 

  18. Stiller, C. A., Benjamin, S., Cartwright, R. A., et al. (1999). Patterns of care and survival for adolescents and young adults with acute leukaemia – a population-based study. British Journal of Cancer, 79(3–4), 658–665.

    Article  PubMed  CAS  Google Scholar 

  19. Fiere, D., Schaison, G., Bancillon, A., & Sebban, C. (1990). What is the best treatment for patients between 15 years and 20 years with acute lymphoblastic leukemia? Comparative results of two protocols, on for adults, one for children. Blood, 76, 270a.

    Google Scholar 

  20. Boissel, N., Auclerc, M. F., Lheritier, V., et al. (2003). Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. Journal of Clinical Oncology, 21(5), 774–780.

    Article  PubMed  Google Scholar 

  21. de Bont, J. M., Holt, B., Dekker, A. W., van der Does-van den Berg, A., Sonneveld, P., & Pieters, R. (2004). Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia, 18(12), 2032–2035.

    Article  PubMed  Google Scholar 

  22. Testi, A. M., Valsecchi, M. G., Conter, V., et al. (2004). Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols. Blood (ASH Annual Meeting Abstracts), 104(11), 1954.

    Google Scholar 

  23. Ramanujachar, R., Richards, S., Hann, I., et al. (2007). Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatric Blood & Cancer, 48(3), 254–261.

    Article  Google Scholar 

  24. Hallbook, H., Gustafsson, G., Smedmyr, B., Soderhall, S., & Heyman, M. (2006). Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: A comparison between a pediatric protocol and an adult protocol. Cancer, 107(7), 1551–1561.

    Article  PubMed  CAS  Google Scholar 

  25. Stock, W., La, M., Sanford, B., et al. (2008). What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of children’s cancer group and cancer and leukemia group B studies. Blood, 112(5), 1646–1654.

    Article  PubMed  CAS  Google Scholar 

  26. Usvasalo, A., Raty, R., Knuutila, S., et al. (2008). Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica, 93(8), 1161–1168.

    Article  PubMed  CAS  Google Scholar 

  27. Pui, C. H., Frankel, L. S., Carroll, A. J., et al. (1991). Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): A collaborative study of 40 cases. Blood, 77(3), 440–447.

    PubMed  CAS  Google Scholar 

  28. Silverman, L. B., Gelber, R. D., Dalton, V. K., et al. (2001). Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber consortium protocol 91-01. Blood, 97(5), 1211–1218.

    Article  PubMed  CAS  Google Scholar 

  29. Amylon, M. D., Shuster, J., Pullen, J., et al. (1999). Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A pediatric oncology group study. Leukemia, 13(3), 335–342.

    Article  PubMed  CAS  Google Scholar 

  30. Douer, D. (2008). Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia? Best Practice & Research. Clinical Haematology, 21(4), 647–658.

    Article  CAS  Google Scholar 

  31. Wetzler, M., Sanford, B. L., Kurtzberg, J., et al. (2007). Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and leukemia group B study 9511. Blood, 109(10), 4164–4167.

    Article  PubMed  CAS  Google Scholar 

  32. Riehm, H., Gadner, H., Henze, G., et al. (1990). Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematology and Blood Transfusion, 33, 439–450.

    PubMed  CAS  Google Scholar 

  33. Tubergen, D. G., Gilchrist, G. S., O’Brien, R. T., et al. (1993). Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Childrens Cancer Group phase III trial. Journal of Clinical Oncology, 11(3), 527–537.

    PubMed  CAS  Google Scholar 

  34. Nachman, J. B., Sather, H. N., Sensel, M. G., et al. (1998). Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. The New England Journal of Medicine, 338(23), 1663–1671.

    Article  PubMed  CAS  Google Scholar 

  35. Arico, M., Valsecchi, M. G., Camitta, B., et al. (2000). Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. The New England Journal of Medicine, 342(14), 998–1006.

    Article  PubMed  CAS  Google Scholar 

  36. Balduzzi, A., Valsecchi, M. G., Uderzo, C., et al. (2005). Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: Comparison by genetic randomisation in an international prospective study. Lancet, 366(9486), 635–642.

    Article  PubMed  Google Scholar 

  37. Abrams, A. N., Hazen, E. P., & Penson, R. T. (2007). Psychosocial issues in adolescents with cancer. Cancer Treatment Reviews, 33(7), 622–630.

    Article  PubMed  Google Scholar 

  38. Ferrari, A., & Bleyer, A. (2007). Participation of adolescents with cancer in clinical trials. Cancer Treatment Reviews, 33(7), 603–608.

    Article  PubMed  Google Scholar 

  39. Spinetta, J. J., Masera, G., Eden, T., et al. (2002). Refusal, non-compliance, and abandonment of treatment in children and adolescents with cancer: A report of the SIOP Working Committee on Phychosocial Issues in Pediatric Oncology. Medical and Pediatric Oncology, 38(2), 114–117.

    Article  PubMed  Google Scholar 

  40. Schiffer, C. A. (2003). Differences in outcome in adolescents with acute lymphoblastic leukemia: A consequence of better regimens? Better doctors? Both? Journal of Clinical Oncology, 21(5), 760–761.

    Article  PubMed  Google Scholar 

  41. Herold, R., von Stackelberg, A., Hartmann, R., Eisenreich, B., & Henze, G. (2004). Acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group (ALL-REZ BFM) experience: Early treatment intensity makes the difference. Journal of Clinical Oncology, 22(3), 569–570. author reply 70-1.

    Article  PubMed  Google Scholar 

  42. Advani, A. S., Jin, T., Ramsingh, G., et al. (2008). Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia. Leukaemia & Lymphoma, 49(8), 1560–1566.

    Article  Google Scholar 

  43. Petersdorf, S. H., Kopecky, K. J., Head, D. R., et al. (2001). Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: A Southwest Oncology Group Study. Leukemia, 15(2), 208–216.

    Article  PubMed  CAS  Google Scholar 

  44. Durrant, I. J., Prentice, H. G., & Richards, S. M. (1997). Intensification of treatment for adults with acute lymphoblastic leukaemia: Results of U.K. Medical Research Council randomized trial UKALL XA. Medical Research Council Working Party on Leukaemia in Adults. British Journal of Haematology, 99(1), 84–92.

    Article  PubMed  CAS  Google Scholar 

  45. Annino, L., Vegna, M. L., Camera, A., et al. (2002). Treatment of adult acute lymphoblastic leukemia (ALL): Long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood, 99(3), 863–871.

    Article  PubMed  CAS  Google Scholar 

  46. Takeuchi, J., Kyo, T., Naito, K., et al. (2002). Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: The JALSG-ALL93 study. Leukemia, 16(7), 1259–1266.

    Article  PubMed  CAS  Google Scholar 

  47. Larson, R. A., Dodge, R. K., Linker, C. A., et al. (1998). A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood, 92(5), 1556–1564.

    PubMed  CAS  Google Scholar 

  48. Hunault, M., Harousseau, J. L., Delain, M., et al. (2004). Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: A GOELAMS trial. Blood, 104(10), 3028–3037.

    Article  PubMed  CAS  Google Scholar 

  49. Kantarjian, H., Thomas, D., O’Brien, S., et al. (2004). Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer, 101(12), 2788–2801.

    Article  PubMed  CAS  Google Scholar 

  50. Huguet, F., Leguay, T., Raffoux, E., et al. (2009). Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study. Journal of Clinical Oncology, 27(6), 911–918.

    Article  PubMed  CAS  Google Scholar 

  51. Mastrangelo, R., Poplack, D., Bleyer, A., Riccardi, R., Sather, H., & D’Angio, G. (1986). Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: Biologic bases for staging, stratification, and treatment. Medical and Pediatric Oncology, 14(3), 191–194.

    Article  PubMed  CAS  Google Scholar 

  52. Smith, M., Arthur, D., Camitta, B., et al. (1996). Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. Journal of Clinical Oncology, 14(1), 18–24.

    PubMed  CAS  Google Scholar 

  53. Larson, R. A., Dodge, R. K., Burns, C. P., et al. (1995). A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and leukemia group B study 8811. Blood, 85(8), 2025–2037.

    PubMed  CAS  Google Scholar 

  54. Boucheix, C., David, B., Sebban, C., et al. (1994). Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: An analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Blood, 84(5), 1603–1612.

    PubMed  CAS  Google Scholar 

  55. Holowiecki, J., Krawczyk-Kulis, M., Giebel, S., et al. (2008). Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. British Journal of Haematology, 142(2), 227–237.

    Article  PubMed  Google Scholar 

  56. Secker-Walker, L. M., Craig, J. M., Hawkins, J. M., & Hoffbrand, A. V. (1991). Philadelphia positive acute lymphoblastic leukemia in adults: Age distribution, BCR breakpoint and prognostic significance. Leukemia, 5(3), 196–199.

    PubMed  CAS  Google Scholar 

  57. Pui, C. H., Gaynon, P. S., Boyett, J. M., et al. (2002). Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet, 359(9321), 1909–1915.

    Article  PubMed  Google Scholar 

  58. Hoelzer, D., Thiel, E., Loffler, H., et al. (1988). Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood, 71(1), 123–131.

    PubMed  CAS  Google Scholar 

  59. Asnafi, V., Beldjord, K., Libura, M., et al. (2004). Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. Blood, 104(13), 4173–4180.

    Article  PubMed  CAS  Google Scholar 

  60. Thiel, E., Kranz, B. R., Raghavachar, A., et al. (1989). Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood, 73(5), 1247–1258.

    PubMed  CAS  Google Scholar 

  61. Gokbuget, N., & Hoelzer, D. (2006). Treatment of adult acute lymphoblastic leukemia. Hematology, 2006, 133–141.

    Article  Google Scholar 

  62. Asnafi, V., Buzyn, A., Thomas, X., et al. (2005). Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: A LALA-94 study. Blood, 105(8), 3072–3078.

    Article  PubMed  CAS  Google Scholar 

  63. Vitale, A., Guarini, A., Ariola, C., et al. (2006). Adult T-cell acute lymphoblastic leukemia: Biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood, 107(2), 473–479.

    Article  PubMed  CAS  Google Scholar 

  64. Meijerink, J. P., den Boer, M. L., & Pieters, R. (2009). New genetic abnormalities and treatment response in acute lymphoblastic leukemia. Seminars in Hematology, 46(1), 16–23.

    Article  PubMed  Google Scholar 

  65. Asnafi, V., Radford-Weiss, I., Dastugue, N., et al. (2003). CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. Blood, 102(3), 1000–1006.

    Article  PubMed  CAS  Google Scholar 

  66. Weng, A. P., Ferrando, A. A., Lee, W., et al. (2004). Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science, 306(5694), 269–271.

    Article  PubMed  CAS  Google Scholar 

  67. O’Neil, J., Grim, J., Strack, P., et al. (2007). FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. The Journal of Experimental Medicine, 204(8), 1813–1824.

    Article  PubMed  CAS  Google Scholar 

  68. Breit, S., Stanulla, M., Flohr, T., et al. (2006). Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood, 108(4), 1151–1157.

    Article  PubMed  CAS  Google Scholar 

  69. Asnafi, V., Buzyn, A., Le Noir, S., et al. (2009). NOTCH1/FBXW7 mutation identifies a large subgroup with favourable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): A GRAALL study. Blood, 113, 3918–3924.

    Article  PubMed  CAS  Google Scholar 

  70. Malyukova, A., Dohda, T., von der Lehr, N., et al. (2007). The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Research, 67(12), 5611–5616.

    Article  PubMed  CAS  Google Scholar 

  71. Stanulla, M., & Schrappe, M. (2009). Treatment of childhood acute lymphoblastic leukemia. Seminars in Hematology, 46(1), 52–63.

    Article  PubMed  Google Scholar 

  72. Cave, H., van der Werff ten Bosch, J., Suciu, S., et al. (1998). Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer – Childhood Leukemia Cooperative Group. The New England Journal of Medicine, 339(9), 591–598.

    Article  PubMed  CAS  Google Scholar 

  73. Coustan-Smith, E., Behm, F. G., Sanchez, J., et al. (1998). Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet, 351(9102), 550–554.

    Article  PubMed  CAS  Google Scholar 

  74. van Dongen, J. J., Seriu, T., Panzer-Grumayer, E. R., et al. (1998). Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet, 352(9142), 1731–1738.

    Article  PubMed  Google Scholar 

  75. Dombret, H., Gabert, J., Boiron, J. M., et al. (2002). Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia – results of the prospective multicenter LALA-94 trial. Blood, 100(7), 2357–2366.

    Article  PubMed  CAS  Google Scholar 

  76. Pane, F., Cimino, G., Izzo, B., et al. (2005). Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia, 19(4), 628–635.

    PubMed  CAS  Google Scholar 

  77. Vidriales, M. B., Perez, J. J., Lopez-Berges, M. C., et al. (2003). Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: Early immunophenotypic evaluation has high clinical value. Blood, 101(12), 4695–4700.

    Article  PubMed  CAS  Google Scholar 

  78. Bruggemann, M., Raff, T., Flohr, T., et al. (2006). Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood, 107(3), 1116–1123.

    Article  PubMed  CAS  Google Scholar 

  79. Gokbuget, N., Raff, R., Brugge-Mann, M., et al. (2004). Risk/MRD adapted GMALL trials in adult ALL. Annals of Hematology, 83(Suppl 1), S129–S131.

    PubMed  Google Scholar 

  80. Fielding, A. (2008). The treatment of adults with acute lymphoblastic leukemia. Hematology American Society of Hematology Education Program, 2008, 381–389.

    Article  Google Scholar 

  81. Todeschini, G., Tecchio, C., Meneghini, V., et al. (1998). Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia, 12(2), 144–149.

    Article  PubMed  CAS  Google Scholar 

  82. Mancini, M., Scappaticci, D., Cimino, G., et al. (2005). A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): Analysis of the GIMEMA 0496 protocol. Blood, 105(9), 3434–3441.

    Article  PubMed  CAS  Google Scholar 

  83. Rowe, J. M. (2009). Optimal management of adults with ALL. British Journal of Haematology, 144(4), 468–483.

    Article  PubMed  Google Scholar 

  84. Hoelzer, D., Thiel, E., Ludwig, W. D., et al. (1993). Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). German Adult ALL Study Group. Leukemia, 7(Suppl 2), S130–S134.

    PubMed  Google Scholar 

  85. Chessells, J. M., Bailey, C., & Richards, S. M. (1995). Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet, 345(8943), 143–148.

    Article  PubMed  CAS  Google Scholar 

  86. Ribera, J. M., Ortega, J. J., Oriol, A., et al. (1998). Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology. Haematologica, 83(3), 222–230.

    PubMed  CAS  Google Scholar 

  87. Stein, A., & Forman, S. J. (2008). Allogeneic transplantation for ALL in adults. Bone Marrow Transplantation, 41(5), 439–446.

    Article  PubMed  CAS  Google Scholar 

  88. Bachanova, V., & Weisdorf, D. (2008). Unrelated donor allogeneic transplantation for adult acute lymphoblastic leukemia: A review. Bone Marrow Transplantation, 41(5), 455–464.

    Article  PubMed  CAS  Google Scholar 

  89. Larson, R. (2008). Allogeneic hematopoietic cell transplantation for adults with ALL. Bone Marrow Transplantation, 42(Suppl 1), S18–S24.

    Article  PubMed  Google Scholar 

  90. Sebban, C., Lepage, E., Vernant, J. P., et al. (1994). Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: A comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 12(12), 2580–2587.

    PubMed  CAS  Google Scholar 

  91. Thomas, X., Boiron, J. M., Huguet, F., et al. (2004). Outcome of treatment in adults with acute lymphoblastic leukemia: Analysis of the LALA-94 trial. Journal of Clinical Oncology, 22(20), 4075–4086.

    Article  PubMed  CAS  Google Scholar 

  92. Ribera, J. M., Oriol, A., Bethencourt, C., et al. (2005). Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica, 90(10), 1346–1356.

    PubMed  CAS  Google Scholar 

  93. Labar, B., Suciu, S., Zittoun, R., et al. (2004). Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin’s lymphoma for patients <or=50 years old in first complete remission: Results of the EORTC ALL-3 trial. Haematologica, 89(7), 809–817.

    PubMed  Google Scholar 

  94. Yanada, M., Matsuo, K., Suzuki, T., & Naoe, T. (2006). Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: A metaanalysis. Cancer, 106(12), 2657–2663.

    Article  PubMed  Google Scholar 

  95. Orsi, C., Bartolozzi, B., Messori, A., & Bosi, A. (2007). Event-free survival and cost-effectiveness in adult acute lymphoblastic leukaemia in first remission treated with allogeneic transplantation. Bone Marrow Transplantation, 40(7), 643–649.

    Article  PubMed  CAS  Google Scholar 

  96. Goldstone, A. H., Richards, S. M., Lazarus, H. M., et al. (2008). In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood, 111(4), 1827–1833.

    Article  PubMed  CAS  Google Scholar 

  97. Thiebaut, A., Vernant, J. P., Degos, L., et al. (2000). Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematology/Oncology Clinics of North America, 14(6), 1353–1366.

    Article  PubMed  CAS  Google Scholar 

  98. Dhedin, N., Dombret, H., Thomas, X., et al. (2006). Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: Analysis of the LALA-85, -87 and -94 trials. Leukemia, 20(2), 336–344.

    Article  PubMed  CAS  Google Scholar 

  99. Gokbuget, N., Arnold, R., Bohme, A., et al. (2007). Improved outcome in high risk and very high risk ALL by risk adapted SCT and in standard risk ALL by intensive chemotherapy in 713 adult ALL patients treated according to the prospective GMALL study 07/2003. Blood (ASH Annual Meeting Abstracts), 110(11), 12.

    Google Scholar 

  100. Ribera, J. M., Oriol, A., Sanz, M. A., et al. (2008). Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. Journal of Clinical Oncology, 26(11), 1843–1849.

    Article  PubMed  CAS  Google Scholar 

  101. Haiat, S., Vekhoff, A., Marzac, C., et al. (2007). Improved outcome of adult acute lymphoblastic leukemia treated with a pediatric protocol: Results of a pilot study. Blood (ASH Annual Meeting Abstracts), 110(11), 2822.

    Google Scholar 

  102. DeAngelo, D. J., Dahlberg, S., Silverman, L. B., et al. (2007). A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts), 110(11), 587.

    Google Scholar 

  103. Douer, D., Watkins, K., Mark, L., et al. (2007). A dose intensified pediatric-like regimen using multiple doses of intravenous pegylated asparaginase in adults with newly diagnosed acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts), 110(11), 2823.

    Google Scholar 

  104. Douer, D., Yampolsky, H., Cohen, L. J., et al. (2007). Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood, 109(7), 2744–2750.

    PubMed  CAS  Google Scholar 

  105. Rytting, M., Thomas, D., Kantarjian, H., et al. (2007). Adaptation of augmented Berlin-Frankfurt-Munster (ABFM) therapy in adolescents and young adults with acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts), 110(11), 4342.

    Google Scholar 

  106. Giri, N., Nair, C. N., Pai, S. K., Kurkure, P. A., Gopal, R., & Advani, S. H. (1987). Avascular necrosis of bone in acute lymphoblastic leukemia. American Journal of Pediatric Hematology/Oncology, 9(2), 143–145.

    Article  PubMed  CAS  Google Scholar 

  107. Mattano, L. A., Jr., Sather, H. N., Trigg, M. E., & Nachman, J. B. (2000). Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the children’s cancer group. Journal of Clinical Oncology, 18(18), 3262–3272.

    PubMed  Google Scholar 

  108. Strauss, A. J., Su, J. T., Dalton, V. M., Gelber, R. D., Sallan, S. E., & Silverman, L. B. (2001). Bony morbidity in children treated for acute lymphoblastic leukemia. Journal of Clinical Oncology, 19(12), 3066–3072.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology Department, EA 3518, Saint-Louis Hospital, Paris Diderot University, 1 avenue Claude Vellefaux, 75010, Paris, France

    Nicolas Boissel

Authors
  1. Nicolas Boissel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Françoise Huguet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hervé Dombret
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicolas Boissel .

Editor information

Editors and Affiliations

  1. Cleveland Clinic Foundation, Euclid Ave. 9500, Cleveland, 44195, Ohio, USA

    Anjali S. Advani

  2. School of Medicine, University Hospitals of Cleveland, Euclid Avenue 11100, Cleveland, 44106, Ohio, USA

    Hillard M. Lazarus

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Boissel, N., Huguet, F., Dombret, H. (2011). Treatment of Acute Lymphoblastic Leukemia in Young Adults. In: Advani, A., Lazarus, H. (eds) Adult Acute Lymphocytic Leukemia. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-60761-707-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-707-5_14

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-706-8

  • Online ISBN: 978-1-60761-707-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation